Royalty Pharma RPRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $718.23M-13.2% | $827.15M+17.7% | $702.62M+93.0% | $363.98M-38.9% | $596.08M-19.7% | ||
| -$477.87M+43.6% | -$847.8M+11.5% | -$958.31M-207% | -$311.98M-162% | $503.92M+200% | ||
| $50.1M-37.8% | $80.54M-45.0% | $146.49M-49.8% | $291.57M-58.9% | $708.78M+1,247% | ||
| -$272.67M+9.0% | -$299.6M— | —— | -$507.81M+46.1% | -$941.3M— | ||
| -$32.3M+89.9% | -$320.25M-204% | $307.04M+167% | -$455.81M-387% | $158.69M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Royalty Pharma generate?
- Royalty Pharma (RPRX) generated $2.6B in operating cash flow over the trailing twelve months.
- Where does Royalty Pharma's cash flow data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
